The clinical experience with the metrix automatic implantable atrial defibrillator  by Tavernier, R. & Jordaens, L.
We measured hpopretoms, low.density hpoprolem (LDL) subclasses and 
part,tie size, hpopreloin (a), homocystemo (Hcys), and markets of thremboszs 
and fibnnolysis in 22 oealthy o!derly men ~ago 74 ~ 3 years, mean 
SO), before and alter 9 weeks of treatment with 05, t n, ~ mg,'day O1 oral 
m~cromted 17/~-estradiol 
Restdt~: LDL-C I-6%), apo.B ( 9%), fnglyceride ( 5%), VLDL-TG 
( - ! 9%) 8nd Ho/s ( - 11%) coneenffahons decreased w~th estradtot, whereas 
HDL-C (*14%) and HDL~-C (*55%) increased Lipoprotein (a) d~d not 
ch,~nge. Fibenogen (13%)  and p!asmln(~gen activator inhibitor.1 (PAl.l) 
(26%)  C~noeflf~ations decreasecl There were no changes ~n thrombotK: 
matkem including thrombln-ant!thrembm I!1 complex, prothrombm fragment 
t 2, O.dim0r, anhthfombm activity, preteln~C an~ S and yon Willebrand factor 
set!pen 
Va~btes Pte-eli1~ogen PO-~t~E~OO~I~, % Ch~lnge p vah~e 
(rne<tn ~ SD) irl~an ~ SOl 
LDL-C~t  14t ~ 2t] 132 ~ 30 63 ~ 12 = 0007 
IG mgd~ t30 s ~ 11.~ ~ 41 4 7 ~. ~0 : O 01 
HDL.C ~.'dt 47 t 0 S3 t I0 .t4 z 12 -1) 001 
HDL3.C n~'~l 23 ~ 13 29 ~ 13 .55 : 72 -0003 
HDL3"C m~2/dl 30 ~ ? 27 ~ (~ a 4 ~ tO ; 0 001 
LOLs~e (nml 207 ~O6 2oa ~ 06 9fi ~ a o0ot 
Hc'y~ ti,M) 67 ~ 3 76 ~ 2 I 1., 09 - OOOt 
CortCtu$iOn. We conclude that k'~v (~se estrogen in men reduces low-den- 
sity hpoprotems, homom/steine tibnn(~en and PlA-1 concentrations w~thout 
.ncfeas=ng markers of thrombotic ~sk 
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~ Lipoprotein(a), Stability of Coronary Reperfuslon 
and Efficacy of Thrombolytic Therapy 
AW Harder. G.J. Davies. Card~otogy D~.~s~en. RPMS Hammersm~th 
HOSl~tal London. UK 
Background: Lq:~,c'~retemt:t~ ',Lpa) promotes atherothrembos=s, however, stud- 
~es dunncj acute my~T, ard~al ..-ttarct=on (AMI) remain mcenclusnte We mves- 
bgatecl the relationship between Lpa and efficacy O1 thromb~lyl~c therap'y 
dunng AM= 
,~c-~; :  Twenty six patients 117 men. 9 women, mean age 57 : 2 years) 
admitted with AM| re~mved i v t-PA (30-60 Mega Units) w~thm 6 hours at the 
onset of Symptoms Coronary recanai=zat~on (TIMI grade 3) was assessed 
by senal adenography and ~n~nuou~ 2 channel ST segment recording was 
used to momtor the stabddy of coronary reperfusmn All pat~enLs received 
oral aspmn and =v hepann Baseline pretreatment Lpa and serum hp~d 
~eveLs were measu(.'~cl Patients ,~ere dtvldecl =n 2 groups: Group 1 ILpa 
levels ::25 mg.,'dl, n = 12) and Group 2 ILpa levels - 25 mg.'dl, n = 14) 
Resuits Age. sex. treatment delay from symptom onset. 90 minute TIMI 
grade and hp=ds levels ~ere similar ~n the 2 groups However. coronary 
recanahzafton time (mean : SD) was significantly prolonged cn group 1 
compared to patients m group 2 t51 = 16 vs 30 ; 17 rain p = 005) 
Recanalizahon t~me correlated pos=hvely w~th Lpa levels (r . 0.9. p ~ 0001 ). 
The number (5 : 1vS. 1 =05.  p - 002) and magmtude (31 ~: 1 mmvs. 
1.2 ~ 1 ram. p .  005) OI recurrent ST elevahon following thrombelysls was 
greater m grOup 1 cOmpared to group 2 
Conclusions: Elevated Lpa =s assooated with delayed and unstable coro- 
naw repedus~on toltowmg ~ v tPA 
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[ 845- i_~ I Rates and Predictors of Embolic Events Following 
Electrical Cardloverslon 
F. Genhle, B.K. Khandhena, KR. Bailey. C Lohse. J.8. Seward. A Jamd 
Taiik. Mayo Chn~c and M,tVO Foundat;on. Rochester. Mmnesota. USA 
Wide vanations (1-7%) in reported rates of embolic events lEE) following 
electrical cardioversion (ECV) exist in the literature. To evaluate EE nsk in 
the Mayo ECV practice, all ECVs (1053. 66% male. mean age 66 = 12.5 
years) between 1990-1994 were studied. Patient as well as atrial tibnllafion 
and anticoagulation (AC) characteristics were recorded. Adequate AC was 
defined as therapeutic International Normalized Ratio / Partial Thromboplas- 
tin -time. AC consisted of warfarin (63.0%). heparin (118%). born (15.9%), 
and none (9.3%). Successful ECV was achieved in 892 pts (85%) who form 
the basis for analysis. The rat3 of EE occurrence within 30 days was 0.78% 
(CI 0.32-1.62%). Two (2.1%) of these occurred in 94 no-AC pts (p = 0.012 
compared to AC pts) The rates of EE wore 027% m ad~uatety ant=co. 
agulated pls versus 1 68% ,n m~dequatety anllcoagutated pts (p = 0 0491 
All 7 events occurred =r, the 51% pts with hypedens~on (p = 0 OCt. ) Four 
occurred in 142 diabetic pts iP 0 001 ) History of coronary affery d~sca~.c~ 
and hyperl=p=dem~& were also segndcant (p 005) corretat~ ot EE Two 
O1 7 events OCCurred among 31 pts with severe letl atna! enfarsement (p .  
0 05) 
Cantles!ads 1) Ovmal! rate of EE following ECV m 0 78%= 2) adequate 
AC at the t~me O1 ECV results in lower rates o1 EE (027%); 3) hypertens~Onr 
d~abetes, and severn loft at~!! enla~rgement am associated with h igher  rates 
O1 EE following ECV: and 4) higher rates of EE (2 t%) are noted m pt~ 
not re~oiwng any AC ECV is ~ safe procedure when pts are adequately 
anl=coagutated 
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~ Hypertens!on Strongly Predict= Early Relapse Atter 
Elective Card!ovemlon of Air!a! Fibrillation 
L O'Toele, A. Wilhams, TR D ,Shaw, IR  Starkey, DB Nodhndge Depfot 
Card~o/og~, Western General Hosl~fat, Ec~nburgh. UK 
Background There h~ been a marked recent mcrea~e =n the use O1 electwe 
DC Cardmvers=on IDCCV) for atnal flbnllstlon (AFt We reviewed our pract*ce 
dunng 1996 to identdy chmcal factors which predict maintenance ol sinus 
rhythm (SR) at st~, week follow up (FU) 
Method: Case note rewew of 88 elective admms~ons for DCCV 
Results: 40% O1 patients had hyperlens=on (PIT) 40'% O1 patients were 
taking am~octarone peer to DCCV Immediate mstoratfon at SR was ach~evecl 
=n 88% O1 attempts but only 47% ot the tctat had maintained SR at FU 
In the 63 patrents undergoing DCCV for the first time, tact'ore pred,.ctmg 
maintenance of SR at FU were re~ewecl Age. sex, the presence ot CAD. 
impaired LV function ard use at digoxln did not predict mmntenance at SR 
3=;.~,*.~n .-,I AF ~rongty predicted maintenance O1 SR at FU (AF clura0on - 6 
months 84%. • 6 montt's 32%; p ~ 0 001 ) as did a d=agnos~s of PiT (SR at FU 
PIT 27%, non-HT 70%; p ~ O001) and use et amiodarene (SR at FU 74% 
vs 38%, p = 0002) After adiustment for durahon of AF or use O1 am~odarone 
the relabonsh~p between a diagnosm of HT and tadure to maintain SR at FU 
became even stronger (duration ac~Jsled odds rat~o; HT vs non-HT pat=eats 
12.6; p - 0.001 amlodarone adius~ed odds rat~o .54: p = O 004) 
Cencl'.~on The pr~pomon O1 I-IT patients cn th~s senes =s h~ghe[ than 
reported pre'.qousty, but similar to that m population-based studies of AF The 
chance of maintaining SR after DCCV =n HT patients =s unacceptably low 
Measures to improve outcome include early DCCV and pre-treatment with 
am~oclarene 
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~ 845-3  i The  Cl inical  Exper ience  With the Metr lx Automat ic  
' Imp lantab le  Atr ia l  Def ibr i l lator  
R Tavem~er, L Jordaens For the Metnx Ir~,est~gators. Umversffafr 
Z~ekenhu~s Gent. Gent. Belgium 
Transven~us atnal defibnllahon has been shown to be efficacious for the 
acute termination of episodes of areal fibnllal~on (AF). However, no data 
exist as fo whether repeated transvenous defibnllatlon using an aulomstlC 
cmplantable atrial defibnllator (laD) would be efficamous. Therefor~ the pur- 
pose O1 this chmcal teal was to evaluate the clinical use O1 the Metnx lAD 
m patients (pts) with uprsod~c, symptomatic AF refrecto~/ tO drug therapy. 
The device and Its 3 leads system (Penmeter nght sinai, Penmeter cereno~ 
sinus delibnllat~on and right ventncular bipolar leads) were ~mplanted in St 
pts (40 mares and 11 females). On average these patients had taken 39 
ant~arrhylhm~c drags that had fa~led to control AF recurrence or were found 
to have intolerable s~de effect These pts were without significant StruC~urat 
head d~sease and shghtly enlarged nght stnum (mean LA size 4 4 ~ 0 8 
cm). Dunng the study penocl of 20 months (mean pt follow-up 259 : 138 
days), 41 pts have exbenenced 252 spontaneous AF episodes (SE) with 
an average of 6 episodes per patient Excluding the throe epcsode5 that 
were !rested dunng ADFT testing. 675 synchron=zc"d shocks have been de- 
livered for the remmmng 249 SE (average 27 shocks per epcsode) with no 
ewdenoe of ventncutar prearrhythm~a One pstcent had a shock dehvered 
and had subsequent spontaneous conversion pnor to full delivery of ther- 
apy. One pabent had 4 SE where AF recurred shodly after the sucCesstul 
conversions. Three of these episodes were terminated with pharmacologi- 
cal interventions and one episode was terminated spontaneously. D~l;~ from 
these 8 episodes, including the 3 treated dunng ADFT testing, were ex- 
cluded =n the efficacy calculabons. The device has successfully terminated 
95=0 of the episodes although some patients had AF recurrence ~hortty ~; 
tar successful detibnllation. Taking th~s recurrence of AF into consideret¢on. 
the clinical efficacy of the defibnllat~on therapy was 77.4%. One pabent. 
due to frequent SE (1-2 per week) unaffected by the device unden,~ent AV 
junctional ablation with permanent pacing Prompt termmatren of AF has 
196A ABSTRAC*I'S - Oral JACC Fcbntary 19t)8 
otlowod for 50 of 51 pt~ to remain in sinus rhythm during their individual 
follow-up period, 
Conclusion: Motfix lAD Ilns boon operating as intended in lhe~o patients 
The clinical trial resells with the Molrlx lAD syslem have boon promls=ng in 
tllnl the majority of tile pts have experienced evice terminated spontnneous 
opi~Qdo~ and have fl~oroby boon eLlle to remnln tn sinus rhythm, 
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~ Echocardlographla Predl©tora for Maintenance of 
£;Inua Rhythm Following Suc~aeatui Internal Atrial 
DMIbrillation of Chronla Atrial FlbrlllMIon 
H, Omran, W, Juno, B, Rang, ~, Illlon, R, Sgl~impl, H B~ollor, C, Wotport, 
I],, L(ldorlt~, Dop~Irtte~nt of Cnrdlelog~ Llni~r~lfj, of t]nnn, Bonn, Germnny 
B~ckground: Chront¢~ slrlnl flbrlltafton (AF) v, hi~;h i~ resistanl to oxtorn~'d o10c. 
Irlosl DC-~hock or pharmacological onrdioversion may be stt~cocMully car. 
dlovorted by tnfornnt atrial defibrillation (tAD), However, to avoid unne~soo. 
~aq/ lAD In patients wllh chronic AF il ts important In predict ltltl p~ttents 
whicl~ will revert to AF, The aim ot tile study was to delermlno, wllother 
ochoc~rdtogrophlc p~ramolor~ may predict Ilia recurmnt:e ot AF, 
Method.~; 31 paltanls wilh chronlc~ AF (~3 m, 8 f, ago 50 t g yearn, durattnn 
~f the I~ l  episode 14£1 t 130 dftys) undol~vonl StlCCesslol (AI~. fi months 
following lAD the ro~uHonco f AF was n~ftosaed, Loll atrial dt,"~metor (LAD), 
loll vontricular ejection hnction (EFt, mnxlmam loll ~trlnl appaodngo otoa 
(LAAflroa) nnd left ~trtnl ~ppond~go luncllon as assossQd by peak emptying 
votOClllOs el fhn t AA (LAAv) were nn~lyzed to determine the recurrence el 
AF, 
Re.'~tdts: 3 p~ttonts wore Iosl 1o Iollow up ~ months attar lAD 50% el 
p~t(~nts h~d rocurmnoo of AF 
EF (%1 LAD (errs) I,AA ='t~Ol~ (cm~) LAAv fro(st 
SR(,~ 14) 50 ~ 1,t 42 * (It'~ 5,4 ~ 1 7 a50 ~ 02 
AF(n~ 14~ 5t = 13 45 = e? ti;.~ 1 21 026 ~ et  
The odd~ ratio for recurrence el AF Is 613 (95% conlidooco intowal: 
t 63-,-2~,03) wlll~ a LAAv • 0.35 m/s, 
Conclusions ElOcllon fraction and loft final size are not predictive of 
recurrence Of ntrlnl flbnnntton following succosslul internal alrial defibrillation 
o1 chronic atrial fibrillalion, However, depressed loll atnnt appendage luncbon 
tory be used as n marker to identify those pnllonts which wdl revert to atnal 
fibrillation after internal atrial defibr~nahon of chronic areal hbrdlahon 
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~ ]  Electrlea, or Pharmacolonlc Cerdloverslon of Atria, 
Flbr I atlon: Does the Ven'trlole Really Care? 
JIk~ DoCara, VM Abascal, R,H Folk Boston Umv~rslty Sch~'~l of 
Mechcine. ~oston, MA, USA 
Atfial fibnll~lion (AFt may adversely affect post-cardiovorsion {CV) atnal 
function and cause reversible vontrtcular dy lunction. Controversy exists 
whether peal CV atrial stunning is less with pham'lncoleg~c (pharm) CV than 
oloctncal CV, but no study has addressed the relative effects of pharm and 
olectfical CV on pesI-CV venlncular hemodynamics. We thus performed 
quantitatwe cho-Doppler =n 18 pts who I~ad pl~armacologtc conversion el 
AF after oral dofotitido and compared them to 19 pts rcqt.nng eloclfical CV 
receiving the same drag, Baseline parameters wore the same in both groups. 
For the 37 pt, CV was associated wilh a statistically signif*cant decrease in 
HR and increase in stroke volume (SV) without significant change in cardiac 
output (CO) or eieclion fraction (EFt, Companson of percentage change in 
homodynamic parameters in pharm and electncally converted pf showed no 
difference between Iho groups. 
% Change in Homodvnarn=cs Alter qestorah~,n ofNSR" 
HR SV CO EF 
Ph~m~ CV ~74~o +1 p,o,, 3~'- ÷31"o 
Electrical C ~t t 67% + 175% 0% +74% 
• D = tl~ tot ~ comparl$oP, s between pharrl~ L~nd electric CV 
Conclu~ ,as: Although cardioversion of AF to NSR is asso,':ialed with 
s=gni[;cant -,,angos in hemodynam;cs and stroke volume, the mode of CV 
{electrical ~t pharmacologic) has no effect upon these changes. Thus any 
adverse effects of CV on the atrium are nol transmitted to the ventricle 
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1845-61 Atrial Fibrillation: Favorable Effects of Flecelnlda In 
"rranavenoua Low Energy Internal Atrial 
Carclloverslon 
G. Bonani, M, Biffi, A, Capucc*, G. Bronzetti, G=M Ayem, A, Bran~i, 
B, Mngnttni, Institute of Cardiology, University of Elofogntl, Italy: In Control 
Inc,, Redmond WA, USA 
The effects of intravenous (i,v,) flocninldo (FL) worn tested in 24 pntionls (pts) 
submitted to transvonous low (~norgy c~rdiovomion (CV): 19 had chronic 
atrial fibrillation (OAF), B pt~, had pamwysm,'ll atrial hbnllaflon (PAF), R wav~) 
~'tn=~,rontsod 3/3 ms biph~sio sllocks worn delivered t~Ohvoon fight fltna! 
sad ooronsPf sinus olootmdos, by 40V stops, beginning at 20-.50 V up to 
convomion or to 400-~50V, Alter successful CV, ~ust~lnod AF was indocod, 
Ilion i,v, FL (2 mg/kg) woe, administered and CV was tested again, Shocks 
for CV worn repeated altar FL ovco in p!s, not converted at baseline. 
Results: In CAF CV was effective in 13/t9 (6Q%) pts. at baseline and m 
10119 (84%) pt~,, allot FL, In 3 ply. oonvorsion was obtained only alter FL In 
PAF CV was effective in all lhe pts, 0ifh0r al baseline and alter FL Alter FL 
sign!hoof! reductions io oltecIw0 shocks !oadlfig edge voltages (CAF = from 
3~t t 38 lo 284 t 54 V, p - 0.005; PAF = 184 r 2;' to 130 r 34 V p .. 0.005) 
and ~rrespondlng energies (CAF = from 4,4~ r 1 37 to 3 50 t t 5t J, P .  
0.005; PAF = from 1tab t 02910084 t 0.2£i J, p ~ 001) were obsente(t 
logethor with a stgnllicanl roduc!ton in subjective score for shock induco¢l 
discomfort (from 4.29 t O81 to 3.71 t O 83, p ~ 0.005) in pts. not requmng 
sod~tlon (75"0) No ventncular proarrhylhmlc effects were observed 
In eonclusloa i.v FL has favorable effects m transvenous CV because 
It Iowols dohbnllatloo energy requirements and consoquenOy lowers shock 
Induced d~soomfort Moreover FL may moroaso the proc, odure success r~te 
m OAF, 
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~ 846-2J Pmthrombotlc and Reduced Flbrinolytlc State in 
Association With Homocystelnemia: The 
Framlngham Offspring Study 
GH. Toiler, H. Silborshatz, R.B. D'Agostino, P WF Wilson. P Suthedand, 
I Lipmska, MA. Milliemes, PF. Jacques, A. Bostom, J. Selhub Beth Israe~ 
Deaconess Afedtca/Center. Frammgham Heart Stu~'. Boston. MA. USA 
The mechanism by which elevated homocystome levels increase the nsk of 
cardiovascular disease (CVD) has not been well explained Since thrombosis 
plays a meier role m the onset of CMD. we deten~med whether homo~,s- 
fame levels were associated with thrombotic and fibnnolyttc measures. We 
studied 2717 subjecls wilhoul known CVD trom cycle 5 el the Frammgham 
Offspnng Study (1234 men. 1483 women). Fasting homocysteine levels were 
measured as were plasminogen activator inhibitor antigen (PAI-t } and tissue 
ptasminogen activator antigen (TEA), yon Willebrand Factor. Faclor VII. and 
llbnnogen, The age and gender adjusted associations were determined using 
regression analysis. Results were similar by gender, although the trends were 
stronger among women The signdicanl assoc*ations remained when further 
adiustmg tor body mass index, smoking, diabetes, total and HDL-cholesterol. 
and triglycerides 
Mean values by Qglntllo ot HomocystOmo Level 
UnLt 1 st 2nd 3rd 4th 5 Ih trend In) 
'~AI- 1 (ngq'nl) 20 B 21 9 22 1 23 5 22 9 0 003 
TPA (ng'ml) 884 858 902 936 941 0001 
vWF (%) 124 124 127 129 t29 0011 
FactowVII (%) 98 100 100 100 t00 0 008 
Fibnnogen (rag dl) 299 306 310 309 300 0 943 
Conclusion: Higher homocysteine levels were associated with a pro- 
thrombotic and reduced fibrinolytic stale. This may represent a mechanism 
by which homoeysleine levels modify cardiovascular risk, 
